NR

Neurobo Pharmaceuticals IncNASDAQ NRBO Stock Report

Last reporting period 30 Sep, 2023

Updated 25 Nov, 2024

Last price

Market cap $B

0.027

Micro

Exchange

XNAS - Nasdaq

NRBO Stock Analysis

NR

Uncovered

Neurobo Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.027

Dividend yield

Shares outstanding

18.972 B

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2016-08-05. The firm is engaged in providing therapeutic programs designed to impact a range of indications in coronavirus, neurodegenerative and cardiometabolic disease. Its products include ANA001, Niclosamide, NB-01 and NB-02. The ANA001 is an oral niclosamide formulation and is being developed as a treatment for patients with moderate coronavirus disease. Niclosamide is a potential oral antiviral and anti-inflammatory agent and being studied in a 60-subject Phase II clinical trial conducted in the United States. NB-01 primarily focused on the development of a treatment for painful diabetic neuropathy (PDN). NB-02 has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid beta plaque deposition.

View Section: Eyestock Rating